Summary
Cilostazol is significantly more effective than aspirin in preventing recurrent stroke and is associated with fewer hemorrhagic events. This article discusses findings from the Cilostazol Stroke Prevention Study II [CSPS II].
- neurology
- cerebrovascular disease
- ischemia
- neurology clinical trials
- © 2010 MD Conference Express
Tools
Cilostazol for the Prevention of Recurrent Stroke: Results from CSPS II
Permalink:
Table of contents
Cited By...
- No citing articles found.